This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2010 by The University of Hong Kong.
Recruitment status was:  Recruiting
Information provided by:
The University of Hong Kong Identifier:
First received: August 11, 2006
Last updated: July 27, 2010
Last verified: July 2010


  • To evaluate the efficacy of capecitabine in combination with oxaliplatin (XELOX) in terms of overall response rate (based on RECIST criteria) in patients with metastatic NPC without prior chemotherapy for relapse.


  • To evaluate the efficacy profile of oxaliplatin (XELOX) in patients with metastatic NPC in terms of time to progression of disease, survival time, duration of response and complete response rate.
  • To study the safety and tolerability of the regimen in patients with metastatic NPC.

Condition Intervention Phase
Nasopharyngeal Neoplasms Drug: Oxaliplatin Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center Phase II Trial of Capecitabine in Combination With Oxaliplatin (Xelox) as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma (NPC)

Resource links provided by NLM:

Further study details as provided by The University of Hong Kong:

Primary Outcome Measures:
  • Overall response rate (based on RECIST criteria) [ Time Frame: From the beginning to the end of the study ]

Secondary Outcome Measures:
  • Time to progression [ Time Frame: From the beginning to the end of the study ]
  • Overall survival time [ Time Frame: From the beginning to the end of the study ]
  • Adverse events [ Time Frame: From the beginning to the end of the study ]

Estimated Enrollment: 42
Study Start Date: July 2006
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Oxaliplatin
130mg/m² infusion day 1, repeat every 21 days


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed poorly differentiated or undifferentiated nasopharyngeal carcinoma (WHO type II and III) with distant metastasis (ie. other than loco-regional disease). Patients with stage IVc disease, ie. distant metastases on presentation are also eligible.
  • Have at least one measurable lesion according to RECIST which has not been irradiated.
  • WBC count ≥ 3 x 10^9 /L with neutrophils ≥ 1.5 x 10^9 /L, platelet count ≥ 100 x 10^9 /L and Hb ≥ 9g/dL.
  • Serum creatinine ≤ 1.25 ULN
  • Be ambulatory and have a Karnofsky Performance Status of ≥ 70% at study entry.
  • Recover from prior radiotherapy prior to study entry
  • Effective contraception for both male and female if the risk of conception exists.
  • Able to swallow and retain oral medication.

Exclusion Criteria:

  • Previous cytotoxic chemotherapy for recurrent or metastatic NPC.
  • Previous exposure to oxaliplatin and/or capecitabine.
  • Pregnant or lactating women. Women of childbearing potential with either positive or no pregnancy test at baseline. Women of childbearing potential not using a reliable and appropriate contraceptive method. (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential)
  • Sexually active males unwilling to practice contraception during the study.
  • Clinically significant cardiac disease (eg. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.
  • Patients with a history of central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.
  • History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.
  • Abnormal blood counts, AST, ALT, bilirubin and/or serum creatinine beyond the limits specified in the inclusion criteria.
  • Radiotherapy within 4 weeks of treatment start or prior radiotherapy to the indicator lesion(s) being measured in the study (newly arising marker lesions in previously irradiated areas are acceptable).
  • Major surgery within 4 weeks of the start of study treatment, without complete recovery.
  • Participation in any investigational drug study within 4 weeks preceding the start of treatment.
  • Symptomatic peripheral neuropathy NCI-CTCAE grade ≥ 2.
  • Known allergic/hypersensitivity reaction to any of the components of study treatments.
  • Serious uncontrolled intercurrent infections.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00363831

Contact: Public Registry GMA

Hong Kong
Sanofi-aventis Recruiting
Hong Kong, Hong Kong
Sponsors and Collaborators
The University of Hong Kong
Study Director: Iris Chan Sanofi
  More Information

Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00363831     History of Changes
Other Study ID Numbers: L_9863
Study First Received: August 11, 2006
Last Updated: July 27, 2010

Additional relevant MeSH terms:
Nasopharyngeal Neoplasms
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Nasopharyngeal Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents processed this record on August 21, 2017